Continue Reading
Full article on Bloomberg
US, Lilly, Novo to Announce Deal to Cut GLP-1 Prices (Trump's Remarks)
{# Share Buttons Partial Variables: share_title — text to pre-fill in share dialogs share_url — canonical URL to share (use request.build_absolute_uri in parent) #}Market Intelligence Analysis
AI-Powered
Why This Matters
Eli Lilly and Novo Nordisk have secured deals with the Trump administration to cut prices for their GLP-1 weight-loss drugs in exchange for tariff relief and wider Medicare access.
Market Impact
Market impact analysis based on bullish sentiment with 80% confidence.
Sentiment
Bullish
AI Confidence
80%
Article Context
Note: This is a brief excerpt for context. Click below to read the full article on the original source.
Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. The deals with Lilly and Novo, announced Thursday at a White House event with President Donald Trump, will make some of the most popular drugs in the world available to certain people on Medicare, the government health plan for older Americans, according to senior administration officials. (Source: Bloomberg)
Original article published by
Bloomberg
on November 6, 2025.
Analysis and insights provided by AnalystMarkets AI.
Analysis and insights provided by AnalystMarkets AI.